LAUSANNE, Switzerland, Oct. 31,
2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:
ADCT), a commercial-stage global leader and pioneer in the field of
antibody drug conjugates (ADCs), today announced that it will host
a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the
third quarter 2024 and provide operational updates.
To access the conference call, please register here. The
participant toll-free dial-in number is 1-800-836-8184 for
North America and Canada. It is recommended that you join 10
minutes before the event, though you may pre-register at any time.
A live webcast of the call will be available under "Events and
Presentations" in the Investors section of the ADC Therapeutics
website at ir.adctherapeutics.com. The archived webcast will be
available for 30 days following the call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global
leader and pioneer in the field of antibody drug conjugates (ADCs).
The Company is advancing its proprietary ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in
London and New Jersey. For more information, please
visit https://adctherapeutics.com/ and follow the Company
on LinkedIn.
ZYNLONTA® is a registered trademark of ADC
Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. In some cases you can identify
forward-looking statements by terminology such as "may", "will",
"should", "would", "expect", "intend", "plan", "anticipate",
"believe", "estimate", "predict", "potential", "seem", "seek",
"future", "continue", or "appear" or the negative of these terms or
similar expressions, although not all forward-looking statements
contain these identifying words. Forward-looking statements are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to: the
expected cash runway into mid-2026 the Company's ability to grow
ZYNLONTA® revenue in the
United States; the ability of our partners to commercialize
ZYNLONTA® in foreign markets, the timing and amount
of future revenue and payments to us from such partnerships and
their ability to obtain regulatory approval for
ZYNLONTA® in foreign jurisdictions; the timing and
results of the Company's or its partners' research and development
projects or clinical trials including LOTIS
5 and 7, ADCT 601 and 602 as well as early research in
certain solid tumors with different targets, linkers and payloads;
the timing and results of investigator-initiated trials including
those studying FL and MZL and the potential regulatory and/or
compendia strategy and the future opportunity; the timing and
outcome of regulatory submissions for the Company's products or
product candidates; actions by the FDA or foreign regulatory
authorities; projected revenue and expenses; the Company's
indebtedness, including Healthcare Royalty Management and Blue Owl
and Oaktree facilities, and the restrictions imposed on the
Company's activities by such indebtedness, the ability to comply
with the terms of the various agreements and repay such
indebtedness and the significant cash required to service such
indebtedness; and the Company's ability to obtain financial and
other resources for its research, development, clinical, and
commercial activities. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K and in the Company's other periodic and current
reports and filings with the U.S. Securities and Exchange
Commission. These statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance, achievements or prospects to be materially different
from any future results, performance, achievements or prospects
expressed in or implied by such forward-looking statements. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this document.
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download
multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-host-third-quarter-2024-financial-results-conference-call-on-november-7-2024-302291883.html
SOURCE ADC Therapeutics SA